Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Bodnar, Edward Scolnick, George Daley, Bennett Shapiro Join Elixir CAB; Myra Williams, Michael Lack Named to ProSanos Board

NEW YORK, Dec. 3 (GenomeWeb News) - Andrew Bodnar, Edward Scolnick, George Daley, and Bennett Shapiro have been appointed to the newly-formed clinical advisory board at Elixir Pharmaceuticals, the Cambridge, Mass., drug discovery company said today.


Bodnar is senior vice president, strategy and medical & external affairs at Bristol-Myers Squibb.  Prior to joining Bristol-Myers Squibb, he was associate chief of internal medicine, acting chief of cardiology, and director of the internal medicine residency program at Massachusetts General Hospital in Boston.


Edward Scolnick is president emeritus at Merck Research Labs. Before joining Merck, he was chief of the laboratory of tumor virus genetics at the National Cancer Institute.


George Daley is a partner at venture firm MPM Capital, as well as the firm's chief medical and scientific advisor. He is also an associate professor of biological chemistry and molecular pharmacology and pediatrics at Harvard Medical School, and a staff member in hematology/oncology at the Children's Hospital, Dana Farber Cancer Institute, and Brigham and Women's Hospital. Previously, Deley was Whitehead Fellow at the Whitehead Institute for Biomedical Research and assistant professor of medicine at Harvard Medical School and the Massachusetts General Hospital.


Bennett Shapiro retired this year from Merck Research Labs, where he was senior vice president, worldwide licensing and external scientific affairs. He was previously vice president of basic research at MRL, and prior to that, was professor and chairman of the department of biochemistry at the University of Washington.


"The purpose of the Elixir CAB is to provide guidance on selecting clinical indications and establishing mission critical paths into and through the clinic," Bard Geesaman, vice president of medical development at Elixir, said in a statement. "This is a particularly important task for a company such as ours where the discovery platform involves models of aging and longevity rather than traditional disease-focused approaches."


Myra Williams and Michael Lack have been appointed to the board of directors of ProSanos, the La Jolla, Calif., informatics company said Dec. 2.


Williams is a consultant for the biopharma and bioinformatics/IT industry, and is the former president and CEO of Molecular Applications Group, a genomics IT company. She also has been vice president and worldwide director of R&D information resources for Glaxo Wellcome, and vice president and CIO of Glaxo, as well as vice president, IT for Glaxo Research Institute, and executive director of information resources and strategic planning at Merck Research Laboratories.


Lack is also a biotechnology and informatics consultant, and was until recently COO of Incyte Genomics. Prior to that, he was president and CEO of Silicon Valley Networks, and previously, president and CEO of Presidio Systems. He was also senior VP of product operations at Cadence Design Systems, and division president of the integrated circuit design division, as well as division president of the systems division.


The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.